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METHODS AND MATERIALS: One brachytherapy team at the British Columbia Cancer
Agency has incorporated MReCT fusion into their permanent seed prostate brachytherapy quality
assurance procedure. Several attempts were required to ensure that the diagnostic MR scanner at the
adjoining general hospital performed the desired sequence, providing many examples of suboptimal
scans and underlining the pitfalls for a center trying to incorporate the use of MR scanning into their
brachytherapy program.
RESULTS: The recommended sequence (Fast Spin Echo T2-weighted, repetition time [TR]/echo
time [TE] 4500/90, echo train length [ETL] 10, 20 20 field of view [FOV], 80 bandwidth [BW])
is associated with superior edge detection when compared with those images in which a typical
diagnostic sequence was used. The use of a low bandwidth sequence does not compromise edge
detection or seed identification when compared with a higher bandwidth.
CONCLUSIONS: We have defined a magnetic resonance imaging sequence, which appears to
optimize both prostate delineation and identification of seeds, lending itself to straightforward
fusion with CT images and allowing for less uncertainty in permanent seed prostate brachytherapy
quality assurance.  2013 American Brachytherapy Society. Published by Elsevier Inc. All rights
reserved.Keywords: Prostate neoplasms; Brachytherapy; Magnetic resonance imaging; Quality assuranceIntroduction
Implant quality is an important determinant of outcome
in patients with prostate cancer treated with permanent seed
brachytherapy. Accurate dosimetry provides feedback to
the brachytherapy team, fosters technical changes to
improve quality, and identifies suboptimal implants that
may require corrective measures. Programs with meticu-
lous quality assurance (QA) report higher biochemical
control rates than those where poor-quality implantsust 2011; received in revised form 6 March 2012;
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.1016/j.brachy.2012.03.001predominate. Recent articles from Zelefsky et al. (1) and
Henry et al. (2) report a large variation in implant quality
with inferior biochemical control rates in patients with
low postimplant D90’s (minimum dose received by 90%
of the prostate).
Postimplant dosimetry is very dependent on the quality
of prostate imaging. Computed tomography (CT) imaging
is the accepted standard for evaluation of implant quality,
although the implanted seeds produce artifacts and obscure
the outline of the prostate gland. Prostate volume determi-
nation by CT tends to overestimate the prostate volume
(3, 4) when compared with either ultrasound or magnetic
resonance imaging (MRI). Contrary to the situation with
CT imaging, the presence of brachytherapy seeds does
not affect the quality of prostate imaging using MRI, and
consequently edge detection is superior to that achievable
with CT. The use of MRI has been shown to reducehed by Elsevier Inc. All rights reserved.
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purpose of external beam planning and in the postimplant
setting (5e7).
When MRI is used for the purpose of quality assess-
ment after brachytherapy, it is important that the optimal
scan sequence be selected. The use of a nonoptimal scan
sequence leads to disappointing imaging results that
diminish the value of the scan. In the post brachytherapy
setting, the chosen imaging modality should sharply
define the edges of the prostate while allowing visualiza-
tion of the implanted seeds. The use of the typical diag-
nostic magnetic resonance (MR) sequence does not meet
these requirements and can lead to uncertainty in both
contouring and seed identification. The purpose of this
article is to demonstrate with case reviews what we have
found to be an ideal MR scan sequence for postimplant
assessment after permanent seed brachytherapy. We will
also demonstrate the potential pitfalls that can be encoun-
tered with suboptimal imaging.Methods and materials
The British Columbia Cancer Agency Center for the
Southern Interior is one of four regional sites of the British
Columbia Cancer Agency where prostate brachytherapy
seed implants are performed. Four radiation oncologists
at our center perform permanent 125I seed implants, using
either stranded or loose seeds. MRI and CT imaging are
systematically performed at 30 days postimplant, and are
manually fused using the seeds as fiducial markers. MR
images are used to delineate the prostate gland and relevant
normal structures, and CT is used to determine the location
of the seeds. Both loose and stranded seeds are used, and
patients receiving implants with loose seeds also undergo
plain film imaging of the chest and pelvis. Our brachyther-
apy team meets regularly to review the postimplant
dosimetry.Imaging
Axial MR images of the prostate and lower pelvis are
taken using a 1.5 Tesla Signa GE scanner with the patient
supine. A Fast Spin Echo T2-weighted MR sequence is
used with the following technical parameters: repetition
time (TR)5 4500 msec, echo time (TE)5 90 msec, echo
train length (ETL)5 10, pixel bandwidth (BW)5 80 Hz/
pixel, field of view5 20 20 cm, 3-mm slice thickness,
0-mm gap, acquired matrix sixe5 320 224 with phase
encoding direction along rows, flip angle5 90.
CT images are likewise obtained in the supine position,
imaging the prostate and all seeds visible on the scout
image in 2-mm slices. Catheterization is performed for
urethral localization when required by the oncologist. No
specific bowel preparation is used before either scan butthey are performed sequentially, with the CT following
the MRI generally within half an hour.Results
Figure 1 shows MR images on a patient in whom our
standard sequence is used. Using this sequence, both the
prostate edge and seed locations are easily detectable.
Caudal to the prostate, the plane of fat separating the
urethra and levator ani muscle displays high signal (white)
on T2-weighted images. The prostate apex can be identified
as the most caudal slice, where this ‘‘white’’ plane is lost
and there is low-signal density apparent in this space. Supe-
riorly, bladder neck has different signal intensity than pros-
tatic tissue, allowing identification of the prostate base.
Intraprostatic anatomy is not clearly identified with this
sequence. For instance, the urethra is not as clearly visible
as on a diagnostic scan and the distinction between the tran-
sition and peripheral zones is diminished. However, these
features are not important for the purposes of implant eval-
uation. If urethral localization is desired, catheterization
can be performed at the time of either the MR or the CT.
We have previously acquired MR images using this
sequence with a longer bandwidth of 120 Hz/pixel. With
a lower bandwidth of 80 Hz/pixel, there is a savings of
about 2 min in image acquisition per patient. As our MR
scans are performed at the adjoining general hospital where
MR time is at a premium, this time saving was significant
in obtaining the required number of MR bookings per
week. Reducing the bandwidth reduces the noise and
increases the chemical shift artifact that is expected to
improve the visibility of implanted seeds. Our experience
indicates that the increased static magnetic field (B0)
distortions because of the lower bandwidth do not cause
CTeMRI fusion issues for MR images acquired with the
scan sequence identified in this study. The images obtained
are indistinguishable for both the prostate edge detection
and seed identification. Shorter imaging time also reduces
motion artifact, and improves patient convenience. The
images below (Fig. 2) demonstrate the lack of effect of this
modification on image quality.
A diagnostic sequence is not optimal for the purposes of
evaluating a brachytherapy implant, as demonstrated in
Fig. 3. In a typical diagnostic sequence, the peripheral zone
is relatively isointense with the periprostatic fat, diminish-
ing prostate edge detection. Thus, the readily visible inter-
face between the peripheral and transition zones (‘‘surgical
capsule’’) can be mistaken for the prostate capsule. Even
when one is aware of this issue, the outline of the prostate
can be indistinct, particularly at the apex as shown in Fig. 3.
Although intraprostatic pathology is more readily visible,
this information is not essential to postimplant evaluation.
The prostate brachytherapy program at the British
Columbia Cancer Agency previously explored the use of
MRI in postimplant QA but did not appreciate the
Fig. 1. Magnetic resonance image series of the prostate (repetition time [TR]5 4500 msec, echo time [TE]5 90 msec, echo train length [ETL]5 10, band-
width [BW]5 80 Hz/pixel). Image (b) represents the most inferior slice, where prostate is visible. Images (def) are taken through the midgland. Image (h)
represents the most superior slice, where prostate is visible. Example seed voids are demonstrated with the white arrowheads. LA5 levator ani muscle;
U5 urethra; R5 rectum.
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example of an MR series using a suboptimal sequence,
demonstrating the importance of using a sequence that is
specific to the postimplant setting. Figure 5 shows a patient
in whom motion artifact has impaired seed and prostate
identification, despite the use of the proper sequence.Fig. 2. Magnetic resonance images through the midprostate. A bandwidth
of 120 Hz/pixel was used in the image on the left, and the image on the
right was taken using a bandwidth of 80 Hz/pixel. These images were
taken from the same patient.Discussion
Evaluation of dosimetry after permanent seed brachy-
therapy provides invaluable feedback to the brachytherapy
team, and is essential to individual patient care. Interob-
server variation in prostate contouring using CT alone in
the postimplant setting leads to substantial variation in
dosimetric interpretation (8), and may fail to identify
substandard implants when compared with MReCT fusion
(9). The MR sequence described in this article optimizes
edge detection needed for prostate delineation and allows
adequate identification of seeds and spacers.
High-quality MRI is paramount to meet the dual
purposes of defining the outline of the prostate and clearly
visualizing the seed voids (10, 11). The literature
describing the use of MRI for the purposes of QA after
permanent seed prostate brachytherapy commonly reports
difficulty with fusion and simultaneous identification of
the prostate and seeds. Amdur et al. (12) have described
a method of fusing CT and MR images using a Foley cath-
eter balloon and urethral position as landmarks. However,
such an approach is confounded by prostate deformation
by the catheter and proximal movement of the catheter
Fig. 3. Diagnostic magnetic resonance sequences for 2 patients (aec and def). Technical parameters for these sequences are as follows: repetition time
(TR)5 4080 msec, echo time (TE)5 85 msec, echo train length (ETL)5 13, bandwidth (BW)5 130 Hz/pixel, field of view [FOV]5 34 34 cm, 3-mm
slices, 0-mm gap, 256 256 matrix with phase-encoding direction along rows, flip angle5 90. Images (a) and (d) demonstrate the prostate apex. Images
(b) and (e) are taken from the midgland. Images (c) and (f) show the prostate base. The white arrows demonstrate the interface between the transition zone
and peripheral zone. The black arrows outline the prostate capsule. Note that a Foley catheter is in place in both the patients.
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MR sequences vs. the use of MReCT fusion. The
sequences used in this article were still confounded by
the lack of ability to clearly identify extraprostatic seeds,
and the use of MRI alone appeared to overestimate dosi-
metric parameters vs. MReCT fusion; however, the accu-
racy appeared to be superior to that associated with CT
alone. Katayama et al. (14) have made further advance-
ments in this area by fusing T2* (which allows improved
seed detection) and T2 MR sequences to one another,
observing dosimetry that was at least comparable and
possibly superior to that obtained using T2 MR alone.
For some patients in this series, there were large differences
noted with T2*T2 fusion vs. CTeMR fusion, likely result-
ing from seed identification. Although CT imaging is still
necessary for seed identification, the results reported by
these studies suggest that the use of MRI alone may be
possible in the future. With the single MRI sequenceFig. 4. For unknown reasons, the magnetic resonance (MR) sequence paramete
shorter (3650 sec). Neither the prostate edge nor seed voids are well defined in
so poor until these parameters were reviewed and corrected. Communication wi
of the goals of MR imaging in the postimplant setting.described in our article when compared with two sequences
used by Katayama et al., (14) the seed positions on CT and
signal voids on a single MR sequence can be fused to
within 1e1.5 mm accuracy (9), and thus may be a useful
starting point for centers wishing to incorporate MRI into
postbrachytherapy QA.
The goals of MRI after permanent seed brachytherapy
are distinct from those of diagnostic prostate MRI, and as
discussed above, a diagnostic sequence is not ideal for
the purposes of post brachytherapy QA. The details of diag-
nostic prostate MRI are relevant to both brachytherapy and
external beam radiotherapy and are reviewed elsewhere
(15, 16). Whereas postimplant imaging requires clear pros-
tate edge detection and visualization of seed voids, diag-
nostic imaging strives to enhance intraprostatic detail.
One approach to improve the resolution of MRI in the diag-
nostic realm is to use an endorectal coil. However, if used
in the postimplant setting, this would deform the prostaters were adjusted for a series of patients such that the repetition time was
the images displayed above. It was not understood why the imaging was
th the radiology department is critical to ensure a common understanding
Fig. 5. Example of a poor image quality resulting from motion artifact,
despite the use of the appropriate sequence.
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Also, because the deformed shape does not represent the
natural state of the prostate, the dose calculations will not
correspond to what is actually delivered to the unperturbed
prostate.
McLaughlin et al. (17) found that CT imaging, and
T1-weighted and T1-weighted fat saturation MR, consis-
tently overestimated the prostate volume when compared
with T2-weighted MR and suggested that overestimation
at the prostate base may be a factor in the misperception
of underdosing at the anterior prostate base. T2-weighted
MR also resulted in the best prostatic definition at the
pelvic diaphragm, distinguishing the apex from soft tissue,
and at the base distinguishing prostate from bladder and
seminal vesicle. However, T2-weighted MR was inferior
to both CT and T1-MR sequences in terms of seed defini-
tion, image acquisition time, and cost. The T2-weighted
sequence we have described allows for both adequate seed
definition to allow fusion with CT, and the low bandwidth
reduces acquisition time without compromising edge
detection.
Several barriers exist, which have limited the use of MRI
in the postimplant setting. MRI is costly and access to
machine time may be limited. If one succeeds in obtaining
MRI, the process of fusion of MR and CT requires some
training and adds to the time required for implant evalua-
tion. In our practice, an experienced dosimetrist, physicist,
or physician can complete most of the fusions in only
5e15 min per case. MR as a single-imaging modality,
avoiding the use of CT imaging postimplant, is being inves-
tigated but is not feasible at present as seeds and spacers
leave similar voids and extraprostatic seeds are not well
visualized on MRI.Conclusion
We have defined an MRI sequence, which provides
satisfactory prostate delineation and identification of seeds,
lending itself to straightforward fusion with CT images and
allowing for greater certainty in permanent seed prostate
brachytherapy QA. The choice of the correct MR sequenceis essential in making the additional time and expense of
MRI worthwhile.References
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